NASDAQ:ORKA Oruka Therapeutics (ORKA) Stock Price, News & Analysis $26.53 +0.63 (+2.43%) (As of 09:12 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsSEC FilingsTrends Get Oruka Therapeutics alerts: Email Address About Oruka Therapeutics Stock (NASDAQ:ORKA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oruka Therapeutics alerts:Sign Up Key Stats Today's Range$26.53▼$26.5350-Day Range N/A52-Week Range$18.72▼$53.88Volume852 shsAverage Volume49,797 shsMarket Capitalization$32.10 millionP/E RatioN/ADividend YieldN/APrice Target$40.33Consensus RatingBuy Company OverviewARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products. The Company's business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.Read More… This Crypto Coin Could 10x FASTER Than Bitcoin (Ad)The Bitcoin Halving ignited the 2024 boom, and altcoins are primed to SKYROCKET. Last year we tipped off our community with altcoins that delivered EXPLOSIVE gains. Now, we've uncovered an even bigger potential winner for the 2024 Bitcoin Halving bull run.Click here to take advantage of this time-sensitive offer. Receive ORKA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oruka Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ORKA Stock News HeadlinesOruka Therapeutics (NASDAQ:ORKA) Now Covered by Analysts at Lifesci CapitalSeptember 17 at 6:31 AM | americanbankingnews.comOruka Therapeutics (NASDAQ:ORKA) Now Covered by Analysts at TD CowenSeptember 17 at 5:37 AM | americanbankingnews.comBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.September 17, 2024 | Monetary Gold (Ad)Brokers Set Expectations for Oruka Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ORKA)September 17 at 2:45 AM | americanbankingnews.comBuy Rating on Oruka Therapeutics: Promising Developments in Long-Acting Dermatological and Rheumatologic TreatmentsSeptember 16 at 3:00 PM | markets.businessinsider.comInnovative Antibody Engineering Positions Oruka Therapeutics for Market SuccessSeptember 16 at 3:00 PM | markets.businessinsider.comOruka Therapeutics (NASDAQ:ORKA) Research Coverage Started at Jefferies Financial GroupSeptember 15 at 3:17 AM | americanbankingnews.comBiotech firm enters $200M agreementSeptember 12, 2024 | bizjournals.comSee More Headlines ORKA Stock Analysis - Frequently Asked Questions How have ORKA shares performed this year? Oruka Therapeutics' stock was trading at $27.99 at the beginning of the year. Since then, ORKA stock has decreased by 7.5% and is now trading at $25.90. View the best growth stocks for 2024 here. When did Oruka Therapeutics' stock split? Oruka Therapeutics shares split on the morning of Saturday, January 1st 2000. The 12-1 split was announced on Saturday, January 1st 2000. The newly minted shares were distributed to shareholders after the closing bell on Tuesday, September 3rd 2024. An investor that had 100 shares of stock prior to the split would have 1,200 shares after the split. How do I buy shares of Oruka Therapeutics? Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today9/16/2024Next Earnings (Estimated)10/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:ORKA CUSIPN/A CIK907654 Webwww.arcabio.com Phone720-940-2100Fax720-208-9261EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$40.33 High Stock Price Target$41.00 Low Stock Price Target$40.00 Potential Upside/Downside+55.7%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.18% Return on Assets-19.51% Debt Debt-to-Equity RatioN/A Current Ratio26.61 Quick Ratio26.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$34.72 per share Price / Book0.75Miscellaneous Outstanding Shares1,210,000Free FloatN/AMarket Cap$31.34 million OptionableN/A Beta0.89 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ORKA) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.